about
P2X receptors as targets for the treatment of status epilepticusExtracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cellsDiadenosine polyphosphate receptors. from rat and guinea-pig brain to human nervous system.Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo.The ubiquitin-proteasome system in Huntington's disease.microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus.Is the ubiquitin-proteasome system impaired in Huntington's disease?Looking for novel functions of tau.Sources of extracellular tau and its signaling.Tissue-nonspecific Alkaline Phosphatase Regulates Purinergic Transmission in the Central Nervous System During Development and Disease.TNAP Plays a Key Role in Neural Differentiation as well as in Neurodegenerative Disorders.PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.Extracellular tau is toxic to neuronal cells.Diadenosine tetraphosphate contributes to carbachol-induced tear secretion.Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice.Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.Independent receptors for diadenosine pentaphosphate and ATP in rat midbrain single synaptic terminals.Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079.Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation.Cloning and characterization of two novel zebrafish P2X receptor subunits.P2X7 receptors in rat brain: presence in synaptic terminals and granule cells.Interaction between dinucleotide and nicotinic receptors in individual cholinergic terminals.Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain.Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin.Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease.Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.Neuronal P2X7 Receptor: Involvement in Neuronal Physiology and Pathology.Role of CaCMKII in the cross talk between ionotropic nucleotide and nicotinic receptors in individual cholinergic terminals.Tau triggers tear secretion by interacting with muscarinic acetylcholine receptors in New Zealand white rabbits.Tau Overexpression Results in Its Secretion via Membrane VesiclesP2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage
P50
Q26823175-2601BF5A-C17C-45A1-B654-D73813149CCCQ28118982-98793392-3DA5-4D41-8EFE-A09CD1A73619Q34047309-E669E68E-ADC9-4E72-B3C9-84316C96136CQ34461236-2FD9E005-6B76-474D-BDE9-E22E0DA43F0AQ35755046-7171BD8F-9F8A-442B-B90B-DBECD1FBBC17Q36311198-0DFE20A5-5ADC-4094-8AB4-28A9824AD2E6Q36343295-F824868E-12C3-4AF0-9215-1903210BC922Q36866936-D43EE476-5C57-47DC-9D6B-6B526015906EQ38027934-368BE479-FCD6-4B73-95DF-F0AC67741B40Q38188380-E53757C4-B003-47A3-A069-62641BCBCE87Q38364702-D7508B6F-1393-4A67-A193-6BEBC4D8F0B6Q38556352-B1F2734E-1387-42C3-876B-EA704CBEEEADQ39800916-D50AE4FF-EB36-446C-8540-A9A5949A6D6CQ40242845-93556767-1D06-4DF3-A4CF-250109D79F91Q42114666-44BA1929-2BF6-4DFA-B25D-A6AFF2F037E9Q42478056-593742AF-9257-48BE-B1D8-70E8FE0AA17EQ42722680-968AE0C2-D702-4CCB-8F1A-81BCAA015DB5Q43280390-B54249F3-3EAB-4EC4-B3E0-7CA2E49F963FQ43762329-00BCB464-4A71-45A9-8DE1-7F7C5F095A1AQ43963291-6E4828D1-AC81-437C-9696-D4A0C141EB9AQ43964573-B1943069-6B82-40F3-83B2-51F4CFC5F561Q44071610-4455D2C6-CA4C-4500-A4BF-2D67185DB803Q44626268-3A16B316-F038-48F2-8CD0-F8CA405354C9Q44978731-D075566E-4F6C-4D7F-BC73-E3330DC95C7DQ45292466-CED1BCDD-44BC-47AF-A04A-2B4F44B38A4FQ45295140-39939F11-EACB-48F1-B409-EA72FD654B36Q45295805-0F327D5F-38BA-4F11-896B-324AB25FFB79Q45296946-C1612FA9-C7EF-4AEA-B868-770F51A6F22FQ45305036-FF4F8D41-9DA5-4D40-AD2C-AC600406C1F4Q46601743-F2CFE70B-A149-4E20-9EB7-6C5F53CA4B4EQ48024134-E2D92A56-6599-49B7-8093-1860096C5FB7Q48326246-FFA2DD4A-D8D0-4E09-818D-BECF3C2D4870Q53461004-A5BAAEB2-B002-4B4A-8FCB-852320EA4785Q63883993-2C39E800-CF65-4945-9F9E-F94D2C2EF819Q87720533-ED827713-9CB2-4FAB-93A7-9D0A669BFD88
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1952-4600
@en
name
Miguel Diaz-Hernandez
@ast
Miguel Diaz-Hernandez
@en
Miguel Diaz-Hernandez
@es
Miguel Diaz-Hernandez
@nl
type
label
Miguel Diaz-Hernandez
@ast
Miguel Diaz-Hernandez
@en
Miguel Diaz-Hernandez
@es
Miguel Diaz-Hernandez
@nl
prefLabel
Miguel Diaz-Hernandez
@ast
Miguel Diaz-Hernandez
@en
Miguel Diaz-Hernandez
@es
Miguel Diaz-Hernandez
@nl
P106
P1153
6603055162
P21
P31
P496
0000-0002-1952-4600